$16 Million Capital Raise to Progress Bionomics BNC210 PTSD Trial
Bionomics Limited has announced a capital placement of A$15,991,634 at A$0.145 per share, supported by North American and European investors. This funding enables the Company to advance its Phase 2b clinical trial for BNC210, targeting PTSD, scheduled for mid-2021. The share price reflects a 263% premium compared to its September 2020 capital raise. Following the placement, an Entitlement Offer will allow eligible shareholders to purchase shares at the same price. The initiative minimizes dilution for current shareholders, with significant backing from reputable life sciences funds.
- Raised A$15,991,634 from institutional investors.
- Capital allows progression to Phase 2b PTSD trial.
- Share price reflects a strong premium of 263% to previous raise.
- None.
- Commitments received for a placement of A
$15,991,634 at A$0.14 5 per share - Significant participation from North American and European institutional and sophisticated investors
- This capital raising enables proceeding with the Phase 2b PTSD trial in mid-2021 as planned and sees the Company well capitalised
ADELAIDE, Australia, Feb. 10, 2021 /PRNewswire/ -- Bionomics Limited (ASX: BNO, OTCQB: BNOEF, Germany: AU000000BNO5), a global, clinical stage biopharmaceutical company, is pleased to announce that it has entered into placement agreements with a number of North American and European institutional and sophisticated investors, to raise A
The new shares will be issued at
Following completion of the placement, the Company will commence an Entitlement Offer allowing eligible shareholders the opportunity to acquire new shares at the same price. Further details of the Entitlement Offer will be provided in a subsequent announcement. Under the Subscription Agreement dated 2 June 2020 with Apeiron Investment Group Limited (Apeiron), the family office of entrepreneur and investor Christian Angermayer, Apeiron agreed to recapitalise the Company and assist in securing further equity capital (Subscription Agreement) to fund the Company's BNC210 Phase 2b Clinical trial for the treatment of post-traumatic stress disorder (PTSD).
As part of the capital raising activities approved by shareholders at the General Meeting on 26 August 2020, Apeiron agreed to underwrite the further raising to the amount of A
Dr. Errol De Souza, Executive Chairman of Bionomics said, "We are pleased to have gained further support from overseas investors as we pursue a treatment for patients suffering from PTSD. The placement was strongly oversubscribed and, as such, we were able to substantially minimize dilution to all our current shareholders by limiting the placement to
Apeiron founder Mr Christian Angermayer said "We are pleased to support Bionomics both as an underwriter in this placement and as a long-term shareholder of the Company. We look forward to participating in the Entitlement Offer alongside other investors. PTSD and other mental health disorders are enormous burdens for those that live with them. Bionomics' lead drug BNC210 has already received Fast Track Designation from the FDA and I am confident of the strong potential of the upcoming Phase 2b PTSD trial to drive value for both patients and shareholders."
AUTHORISED BY THE BOARD
About Bionomics Limited
Bionomics (ASX: BNO, OTCQB: BNOEF) is a global, clinical stage biopharmaceutical company leveraging its proprietary platform technologies to discover and develop a deep pipeline of best in class, novel drug candidates. Bionomics' lead drug candidate BNC210, currently in development for initiation of a second Phase 2 trial for the treatment of PTSD, is a novel, proprietary negative allosteric modulator of the alpha-7 (α7) nicotinic acetylcholine receptor. Beyond BNC210, Bionomics has a strategic partnership with Merck & Co., Inc (known as MSD outside the United States and Canada).
Factors Affecting Future Performance
This announcement contains "forward-looking" statements within the meaning of the United States' Private Securities Litigation Reform Act of 1995. Any statements contained in this announcement that relate to prospective events or developments, including, without limitation, statements made regarding Bionomics' drug candidates (including BNC210), its licensing agreements with Merck & Co. and any milestone or royalty payments thereunder, drug discovery programs, ongoing and future clinical trials, and timing of the receipt of clinical data for our drug candidates are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions are intended to identify forward-looking statements.
There are a number of important factors that could cause actual results or events to differ materially from those indicated by these forward-looking statements, including unexpected safety or efficacy data, unexpected side effects observed in clinical trials, risks related to our available funds or existing funding arrangements, our failure to introduce new drug candidates or platform technologies or obtain regulatory approvals in a timely manner or at all, regulatory changes, inability to protect our intellectual property, risks related to our international operations, our inability to integrate acquired businesses and technologies into our existing business and to our competitive advantage, as well as other factors. Results of studies performed on our drug candidates and competitors' drugs and drug candidates may vary from those reported when tested in different settings.
View original content:http://www.prnewswire.com/news-releases/16-million-capital-raise-to-progress-bionomics-bnc210-ptsd-trial-301225600.html
SOURCE Bionomics Limited
FAQ
What is Bionomics Limited's recent capital raising amount?
When is the Phase 2b PTSD trial for Bionomics scheduled to begin?
What is the share price for Bionomics' recent capital placement?
What premium does the recent placement represent over previous capital raises?
How does the new capital raising benefit current shareholders of Bionomics?
